| Journal | The Journal of pharmacology and experimental therapeutics |
| Study Type | Clinical Study |
| Population | Human participants |
CBG is increasingly used by patients for anxiety despite limited pharmacokinetic data to guide dosing or safety considerations. This study reveals unexpected brain penetration patterns and anxiogenic effects that challenge common assumptions about CBG’s therapeutic profile.
Researchers developed a sensitive analytical method to track CBG and its metabolite cyclo-CBG in male mice after intraperitoneal administration of 10 mg/kg CBG. While CBG itself showed limited brain penetration (brain-to-plasma ratio 0.26), its metabolite cyclo-CBG accumulated extensively in brain tissue (ratio 7.1), suggesting local formation. Contrary to anecdotal reports of anxiolytic effects, CBG produced anxiogenic-like behaviors at peak brain concentrations. The study was limited to male mice and a single administration route.
“This preclinical data gives me pause about CBG’s assumed safety profile for anxiety disorders. The dramatic brain accumulation of the metabolite and anxiogenic effects at therapeutic-relevant concentrations warrant careful clinical observation.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How was CBG given to the mice in this study?
Male mice received CBG at 10 mg/kg by intraperitoneal administration. The researchers developed a sensitive analytical method to track both CBG and its metabolite, cyclo-CBG, in the animals after dosing. The work was published in The Journal of Pharmacology and Experimental Therapeutics.
Does CBG itself get into the brain easily?
Not very well in this study. CBG showed limited brain penetration in male mice, with a brain-to-plasma ratio of 0.26, meaning brain levels were roughly a quarter of blood plasma levels. Its metabolite, cyclo-CBG, showed a very different pattern in brain tissue.
What is cyclo-CBG, and why did it stand out?
Cyclo-CBG is a metabolite of CBG. Unlike CBG itself, it accumulated extensively in brain tissue, with a brain-to-plasma ratio of 7.1. The researchers suggest this pattern points to local formation of the metabolite in the brain. It was tracked alongside CBG using the same sensitive analytical method.
Did CBG reduce anxiety-like behavior in the mice?
No. Contrary to anecdotal reports that CBG eases anxiety, it produced anxiogenic-like behaviors, meaning behaviors resembling increased anxiety, in the mice at peak brain concentrations. This is a preclinical finding in male mice and was not tested in people in this study.
What are the main limitations of this CBG mouse study?
The study was limited to male mice and a single administration route, intraperitoneal dosing. Female animals and other routes of administration were not studied, so the findings on brain levels and anxiety-like behavior may not apply to them, and all results come from animals rather than humans.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
